Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis

Amy E. Armstrong, Jamie Dargart, Jennifer Reichek, David O. Walterhouse, Debora Matossian, Richard A. Cohn, Yasmin Gosiengfiao*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Scopus citations


Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6-year-old child with high-risk neuroblastoma who developed renal failure requiring long-term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20mg/m2/day and oral temozolomide 100mg/m2/day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis. Pediatr Blood Cancer 2014;61:949-950.

Original languageEnglish (US)
Pages (from-to)949-950
Number of pages2
JournalPediatric Blood and Cancer
Issue number5
StatePublished - May 2014



  • Chemotherapy
  • Hemodialysis
  • Irinotecan
  • Neuroblastoma
  • Renal failure
  • Temozolomide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this